The Union Cycliste Internationale (UCI) announces that the Swiss rider Patrick Schelling has been sanctioned with a period of ineligibility of four months for a non-intentional anti-doping rule violation. The matter arises as a result of an Adverse Analytical Finding (AAF) for Terbutaline* in a sample collected on 24 February 2020. In accordance with the World Anti-Doping Code (WADC) and the UCI Anti-Doping Regulations (UCI ADR), the period of ineligibility starts on 18 May 2020 and is effective until 17 September 2020. The rider has also been disqualified from all competitive results obtained at the Tour of Rwanda 2020.
The case has been resolved by way of an acceptance of consequences as provided for by the WADC and the UCI ADR.
The UCI will not comment any further.
*Terbutaline is a Prohibited Substance listed under class S3 (Beta-2 Agonists) of the 2020 Prohibited List which is maintained by the World Anti-Doping Agency (WADA) and adopted by the UCI.
The UCI systematically reports potential anti-doping rule violations via its website when a mandatory provisional suspension applies. In cases where there is no provisional suspension, the UCI publicly discloses Anti-Doping Rule Violations only at the end of the proceedings, unless the existence of the AAF is made public by another party before a decision is rendered. Pursuant to Article 7.9.1. of the UCI Anti-Doping Rules, the presence of a Specified Substance such as Terbutaline in a sample does not result in the imposition of a mandatory provisional suspension against the rider, therefore the Rider’s AAF has not been publicly disclosed until now.